Analyst Price Targets — CAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 6, 2026 12:41 pm | — | Evercore ISI | $25.00 | $17.71 | TheFly | Caris Life Sciences price target lowered to $25 from $30 at Evercore ISI |
| May 8, 2026 12:44 pm | Catherine Ramsey Schulte | Robert W. Baird | $22.00 | $15.97 | TheFly | Caris Life Sciences price target lowered to $22 from $28 at Baird |
| May 8, 2026 11:21 am | Mark Massaro | BTIG | $32.00 | $19.84 | TheFly | Caris Life Sciences price target lowered to $32 from $38 at BTIG |
| April 10, 2026 8:45 am | — | Piper Sandler | $21.00 | $17.89 | TheFly | Caris Life Sciences initiated with a Neutral at Piper Sandler |
| February 17, 2026 10:04 am | — | Robert W. Baird | $26.00 | $20.62 | TheFly | Caris Life Sciences initiated with an Outperform at Baird |
| January 5, 2026 2:46 pm | — | Evercore ISI | $38.00 | $26.68 | TheFly | Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI |
| December 22, 2025 11:52 am | Kyle Mikson | Canaccord Genuity | $30.00 | $27.94 | TheFly | Caris Life Sciences price target raised to $30 from $28 at Canaccord |
| December 2, 2025 10:09 am | — | Canaccord Genuity | $28.00 | $26.05 | TheFly | Caris Life Sciences initiated with a Hold at Canaccord |
| August 13, 2025 11:31 am | Mark Massaro | BTIG | $45.00 | $34.78 | TheFly | Caris Life Sciences price target raised to $45 from $38 at BTIG |
| July 13, 2025 3:03 pm | Subbu Nambi | Guggenheim | $32.00 | $26.51 | TheFly | Caris Life Sciences initiated with a Buy at Guggenheim |
Latest News for CAI
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient…
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologies IRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking…
ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewide contract with the Virginia Information Technologies Agency (VITA) to provide Security Operations Center (SOC) services to local government entities across the Commonwealth.
ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CAI.
U.S. House Trading
No House trades found for CAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.